Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Reversible synaptic adaptations in a subpopulation of murine hippocampal neurons following early-life seizures
Bo Xing, … , Delia M. Talos, Frances E. Jensen
Bo Xing, … , Delia M. Talos, Frances E. Jensen
Published January 16, 2024
Citation Information: J Clin Invest. 2024;134(5):e175167. https://doi.org/10.1172/JCI175167.
View: Text | PDF
Research Article Neuroscience

Reversible synaptic adaptations in a subpopulation of murine hippocampal neurons following early-life seizures

  • Text
  • PDF
Abstract

Early-life seizures (ELSs) can cause permanent cognitive deficits and network hyperexcitability, but it is unclear whether ELSs induce persistent changes in specific neuronal populations and whether these changes can be targeted to mitigate network dysfunction. We used the targeted recombination of activated populations (TRAP) approach to genetically label neurons activated by kainate-induced ELSs in immature mice. The ELS-TRAPed neurons were mainly found in hippocampal CA1, remained uniquely susceptible to reactivation by later-life seizures, and displayed sustained enhancement in α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor–mediated (AMPAR-mediated) excitatory synaptic transmission and inward rectification. ELS-TRAPed neurons, but not non-TRAPed surrounding neurons, exhibited enduring decreases in Gria2 mRNA, responsible for encoding the GluA2 subunit of the AMPARs. This was paralleled by decreased synaptic GluA2 protein expression and heightened phosphorylated GluA2 at Ser880 in dendrites, indicative of GluA2 internalization. Consistent with increased GluA2-lacking AMPARs, ELS-TRAPed neurons showed premature silent synapse depletion, impaired long-term potentiation, and impaired long-term depression. In vivo postseizure treatment with IEM-1460, an inhibitor of GluA2-lacking AMPARs, markedly mitigated ELS-induced changes in TRAPed neurons. These findings show that enduring modifications of AMPARs occur in a subpopulation of ELS-activated neurons, contributing to synaptic dysplasticity and network hyperexcitability, but are reversible with early IEM-1460 intervention.

Authors

Bo Xing, Aaron J. Barbour, Joseph Vithayathil, Xiaofan Li, Sierra Dutko, Jessica Fawcett-Patel, Eunjoo Lancaster, Delia M. Talos, Frances E. Jensen

×

Figure 8

Repeated postseizure IEM-1460 treatment prevents synaptic deficits in TRAPed cells.

Options: View larger image (or click on image) Download as PowerPoint
Repeated postseizure IEM-1460 treatment prevents synaptic deficits in TR...
(A) Experimental scheme of post-ELS IEM-1460 treatment. (B) Representative confocal images showing robust TRAPed cells with or without IEM-1460 treatment. (C) No difference in TRAPed cell count between the vehicle (Veh, n = 4) and IEM-1460 (n = 4). Sal, n = 6. *P < 0.05 by Kruskal-Wallis test followed by Dunn’s test. (D) TRAPed cells under DIC. Scale bars: 50 μm (B) and 20 μm (D). (E) Representative EPSC traces at –60 and +40 mV from TRAPed neurons with Veh or IEM-1460. (F) The I-V curves of EPSCs in tdT+ cells show a linear relationship in the IEM-1460 group and an inwardly rectifying relationship in the Veh group. (G) The rectification index was decreased in IEM-1460–treated tdT+ neurons (n = 20 neurons/11 mice) compared to Veh (n = 14 neurons/6 mice). *P < 0.05 by Mann-Whitney U test. (H and I) Example traces and plots of evoked AMPA currents before and after LTP protocol (0.3 ms, 100 Hz, separated by 20 seconds) from Sal, as well as in tdT+ cells with Veh and IEM-1460. Sal- and IEM-1460–treated neurons showed a long-lasting increase in EPSC amplitude, but Veh tdT+ neurons exhibited comparable EPSC amplitude before and after stimulation. (J) Summary of LTP. Sal, n = 8 neurons/4 mice; Veh, n = 8 neurons/5 mice; IEM-1460, n = 9 neurons/5 mice. ***P < 0.001 by 1-way ANOVA followed by Tukey’s test. (K and L) Example traces and plots of evoked AMPA currents before and after low-frequency (5 Hz, 900 pulses) LTD stimulation (LFS) from Sal, Veh, and IEM-1460 groups. Sal and IEM-1460 showed a long-lasting reduction in EPSC amplitude, whereas Veh tdT+ neurons exhibited comparable EPSC amplitude. (M) Summary of LTD. Sal, n = 12 neurons/6 mice; Veh, n = 16 neurons/6 mice; IEM-1460, n = 13 neurons/8 mice. *P < 0.05 by 1-way ANOVA followed by Tukey’s test. Data expressed as mean ± SEM.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts